Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NRG Oncology
University of California, San Diego
Radiation Therapy Oncology Group
University of Michigan Rogel Cancer Center
Radiation Therapy Oncology Group
Bayer
Aragon Pharmaceuticals, Inc.
Janssen Biotech, Inc.
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Institut Cancerologie de l'Ouest
Pfizer
Pfizer
Bristol-Myers Squibb
Montefiore Medical Center
University of California, San Diego
University of Michigan Rogel Cancer Center
University of Kansas Medical Center
Ohio State University Comprehensive Cancer Center
SWOG Cancer Research Network
Pfizer
Janssen Research & Development, LLC
Bristol-Myers Squibb
Ferring Pharmaceuticals
University of California, San Francisco
Boston University
University of Southern California
NantCell, Inc.
Novartis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Progenics Pharmaceuticals, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Blue Earth Diagnostics
Duke University
Ipsen
National Institutes of Health Clinical Center (CC)
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Mayo Clinic
National Institutes of Health Clinical Center (CC)
University of Miami
University of Michigan Rogel Cancer Center
Institut Bergonié
OHSU Knight Cancer Institute
University of Michigan
Imperial College London
Dana-Farber Cancer Institute